A Phase 2 interventional study of Placebo and Vortioxetine (Lu AA21004) in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-05-13.
Sponsored by H. Lundbeck A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 27th largest by enrollment, is the only one that started in 2006, is one of 6 in phase 2, and was the 10th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 426 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
36 studies in Depressive Disorder, Major by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 36 finished, 20 (56%) have results posted.
Among the 36 studies in Depressive Disorder, Major by H. Lundbeck A/S, this one is the 16th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2006, is one of 7 in phase 2, and was the 9th registered.
H. Lundbeck A/S’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 36 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this Venlafaxine-referenced study is to evaluate the efficacy, safety and tolerability of two fixed doses of Vortioxetine in the acute treatment of Major Depressive Disorder (MDD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Vortioxetine (Lu AA21004)
Drug: Vortioxetine (Lu AA21004)
Active Reference
Drug: Venlafaxine XL
capsules, daily, orally
encapsulated tablets, daily, orally
Also known as: Brintellix
capsules, daily, orally
Also known as: Effexor®
Change From Baseline in MADRS Total Score After 6 Weeks of Treatment
The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.
Time frame: Baseline and Week 6
Change From Baseline in MADRS Total Score After 1 Week of Treatment
Time frame: Baseline and Week 1
Change From Baseline in HAM-D 24 Total Score After 6 Weeks of Treatment
The 24-item Hamilton Depression Rating Scale (HAM-D) is based on the 21-item HAM-D plus an additional 3 items (helplessness, hopelessness, and worthlessness). The observer makes his/her assessment on the basis of a specific statement, content, tone, facial expression, and gestures of the patient during the interview, and scores each item from 0 to 2 or 0 to 4. Total score from 0 to 76. The higher the score, the more severe.
Time frame: Baseline and Week 6
Change From Baseline in HAM-A Total Score After 6 Weeks of Treatment
The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.
Time frame: Baseline and Week 6
Change From Baseline in CGI-S Score After 6 Weeks of Treatment
The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.
Time frame: Baseline and Week 6
Change in Clinical Status Using CGI-I Score at Week 6
The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.
Time frame: Week 6
Proportion of Responders at Week 6 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
Time frame: Week 6
Proportion of Remitters at Week 6 (Remission is Defined as a MADRS Total Score <=10)
Time frame: Week 6
Outpatients with Major Depressive Episode (MDE) were recruited from psychiatric settings.
| Milestone | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg |
|---|---|---|---|---|
| Started | 105 | 108 | 100 | 113 |
| Completed | 87 | 98 | 82 | 93 |
| Not completed | 18 | 10 | 18 | 20 |
| Withdrew: Adverse event | 4 | 3 | 7 | 16 |
| Withdrew: Lack of efficacy | 6 | 6 | 3 | 2 |
| Withdrew: Non-compliance | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 2 | 0 |
| Withdrew: Withdrawal of consent | 4 | 0 | 4 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 |
| Withdrew: Administrative or other reasons | 3 | 0 | 1 | 0 |
The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.
| units on a scale | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg |
|---|---|---|---|---|
| Change From Baseline in MADRS Total Score After 6 Weeks of Treatment | -14.50 ± 1.03 | -20.40 ± 1.01 | -20.20 ± 1.04 | -20.92 ± 0.99 |
| units on a scale | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg |
|---|---|---|---|---|
| Change From Baseline in MADRS Total Score After 1 Week of Treatment | -5.04 ± 0.50 | -5.26 ± 0.49 | -5.86 ± 0.51 | -4.50 ± 0.48 |
The 24-item Hamilton Depression Rating Scale (HAM-D) is based on the 21-item HAM-D plus an additional 3 items (helplessness, hopelessness, and worthlessness). The observer makes his/her assessment on the basis of a specific statement, content, tone, facial expression, and gestures of the patient during the interview, and scores each item from 0 to 2 or 0 to 4. Total score from 0 to 76. The higher the score, the more severe.
| units on a scale | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg |
|---|---|---|---|---|
| Change From Baseline in HAM-D 24 Total Score After 6 Weeks of Treatment | -12.23 ± 0.90 | -17.51 ± 0.89 | -17.57 ± 0.92 | -17.32 ± 0.88 |
The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.
| units on a scale | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg |
|---|---|---|---|---|
| Change From Baseline in HAM-A Total Score After 6 Weeks of Treatment | -8.41 ± 0.74 | -11.71 ± 0.75 | -11.41 ± 0.77 | -11.29 ± 0.73 |
The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.
| units on a scale | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg |
|---|---|---|---|---|
| Change From Baseline in CGI-S Score After 6 Weeks of Treatment | -1.55 ± 0.14 | -2.45 ± 0.14 | -2.51 ± 0.15 | -2.58 ± 0.14 |
The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.
| units on a scale | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg |
|---|---|---|---|---|
| Change in Clinical Status Using CGI-I Score at Week 6 | 2.64 ± 0.12 | 2.05 ± 0.12 | 2.04 ± 0.12 | 1.96 ± 0.12 |
| percentage of patients | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg |
|---|---|---|---|---|
| Proportion of Responders at Week 6 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline) | 44.8 | 66.7 | 68.0 | 72.3 |
| percentage of patients | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg |
|---|---|---|---|---|
| Proportion of Remitters at Week 6 (Remission is Defined as a MADRS Total Score <=10) | 26.7 | 49.1 | 49.0 | 55.4 |
Collected over Serious Adverse Events: 6-week double-blind treatment period and 4-week safety follow-up period Other Adverse Events: 6-week double-blind treatment period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/105 (0%) | 53/105 (50.5%) |
| Vortioxetine 5 mg | — | 0/108 (0%) | 63/108 (58.3%) |
| Vortioxetine 10 mg | — | 2/100 (2%) | 66/100 (66%) |
| Venlafaxine 225 mg | — | 1/113 (0.9%) | 78/113 (69%) |
| Event | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg |
|---|---|---|---|---|
| VaricellaInfections and infestations | 0/105 | 0/108 | 1/100 | 0/113 |
| DepressionPsychiatric disorders | 0/105 | 0/108 | 1/100 | 0/113 |
| Brain neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/105 | 0/108 | 0/100 | 1/113 |
| Event | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 10/105 | 32/108 | 38/100 | 38/113 |
| HeadacheNervous system disorders | 26/105 | 23/108 | 25/100 | 32/113 |
| Dry mouthGastrointestinal disorders | 7/105 | 8/108 | 8/100 | 19/113 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 2/105 | 3/108 | 10/100 | 17/113 |
| DizzinessNervous system disorders | 8/105 | 7/108 | 7/100 | 14/113 |
| InsomniaPsychiatric disorders | 5/105 | 7/108 | 6/100 | 14/113 |
| ConstipationGastrointestinal disorders | 1/105 | 1/108 | 3/100 | 11/113 |
| FatigueGeneral disorders | 6/105 | 4/108 | 6/100 | 11/113 |
| VomitingGastrointestinal disorders | 1/105 | 2/108 | 9/100 | 4/113 |
| NasopharyngitisInfections and infestations | 9/105 | 8/108 | 7/100 | 4/113 |
| Age, Continuous(years) | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg | Total |
|---|---|---|---|---|---|
| Mean | 42.0 ± 10.9 | 43.8 ± 11.6 | 42.3 ± 13.1 | 45.0 ± 10.3 | 43.3 ± 11.5 |
| Sex: Female, Male(Participants) | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg | Total |
|---|---|---|---|---|---|
| Female | 69 | 70 | 66 | 62 | 267 |
| Male | 36 | 38 | 34 | 51 | 159 |
| MADRS: Baseline Total Score(units on a scale) | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg | Total |
|---|---|---|---|---|---|
| Mean | 33.9 ± 2.7 | 34.1 ± 2.6 | 34.0 ± 2.8 | 34.2 ± 3.1 | 34.0 ± 2.8 |
| Baseline 24-item HAM-D Total Score(units on a scale) | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg | Total |
|---|---|---|---|---|---|
| Mean | 29.7 ± 5.0 | 29.9 ± 5.4 | 29.3 ± 5.6 | 29.4 ± 5.0 | 29.6 ± 5.2 |
| HAM-A: Baseline Total Score(units on a scale) | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg | Total |
|---|---|---|---|---|---|
| Mean | 22.9 ± 5.9 | 21.7 ± 6.2 | 22.3 ± 5.6 | 22.0 ± 5.5 | 22.2 ± 5.8 |
| CGI-S: Baseline Severity Score(units on a scale) | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Venlafaxine 225 mg | Total |
|---|---|---|---|---|---|
| Mean | 5.1 ± 0.7 | 5.2 ± 0.7 | 5.1 ± 0.7 | 5.2 ± 0.7 | 5.2 ± 0.7 |
No study locations are listed for this record.
The record gives a start of Aug 2006, a primary completion of Aug 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 6 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine